ALK-Abelló A/S (ALK-B.CO)
DKK 144.1
(-3.03%)
DKK 144.1
(-3.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 291 Million DKK | -38.74% |
| 2022 | 475 Million DKK | -7.95% |
| 2021 | 516 Million DKK | -20.0% |
| 2020 | 645 Million DKK | -4.3% |
| 2019 | 674 Million DKK | 51.12% |
| 2018 | 446 Million DKK | -25.17% |
| 2017 | 596 Million DKK | 23.4% |
| 2016 | 483 Million DKK | 2.99% |
| 2015 | 469 Million DKK | 1240.0% |
| 2014 | 35 Million DKK | 133.33% |
| 2013 | 15 Million DKK | 110.34% |
| 2012 | -145 Million DKK | 65.48% |
| 2011 | -420 Million DKK | -107.92% |
| 2010 | -202 Million DKK | 47.4% |
| 2009 | -384 Million DKK | 10.49% |
| 2008 | -429 Million DKK | 55.36% |
| 2007 | -961 Million DKK | 2.44% |
| 2006 | -985 Million DKK | 81.94% |
| 2005 | -5.45 Billion DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 87 Million DKK | -61.67% |
| 2024 Q1 | 227 Million DKK | -21.99% |
| 2023 Q2 | 565 Million DKK | 26.12% |
| 2023 Q1 | 448 Million DKK | -5.68% |
| 2023 FY | 291 Million DKK | -38.74% |
| 2023 Q4 | 291 Million DKK | -43.05% |
| 2023 Q3 | 511 Million DKK | -9.56% |
| 2022 Q2 | 444 Million DKK | -8.83% |
| 2022 Q4 | 475 Million DKK | 10.72% |
| 2022 Q3 | 429 Million DKK | -3.38% |
| 2022 Q1 | 487 Million DKK | -5.62% |
| 2022 FY | 475 Million DKK | -7.95% |
| 2021 FY | 516 Million DKK | -20.0% |
| 2021 Q1 | 560 Million DKK | -13.18% |
| 2021 Q2 | 579 Million DKK | 3.39% |
| 2021 Q3 | 566 Million DKK | -2.25% |
| 2021 Q4 | 516 Million DKK | -8.83% |
| 2020 FY | 645 Million DKK | -4.3% |
| 2020 Q1 | 663 Million DKK | -1.63% |
| 2020 Q2 | 679 Million DKK | 2.41% |
| 2020 Q3 | 778 Million DKK | 14.58% |
| 2020 Q4 | 645 Million DKK | -17.1% |
| 2019 Q4 | 674 Million DKK | -19.09% |
| 2019 Q1 | 671 Million DKK | 50.45% |
| 2019 Q2 | 844 Million DKK | 25.78% |
| 2019 Q3 | 833 Million DKK | -1.3% |
| 2019 FY | 674 Million DKK | 51.12% |
| 2018 Q3 | 557 Million DKK | -9.43% |
| 2018 Q4 | 446 Million DKK | -19.93% |
| 2018 FY | 446 Million DKK | -25.17% |
| 2018 Q1 | 583 Million DKK | -2.18% |
| 2018 Q2 | 615 Million DKK | 5.49% |
| 2017 FY | 596 Million DKK | 23.4% |
| 2017 Q2 | 524 Million DKK | -18.63% |
| 2017 Q1 | 644 Million DKK | 33.33% |
| 2017 Q4 | 596 Million DKK | -11.57% |
| 2017 Q3 | 674 Million DKK | 28.63% |
| 2016 FY | 483 Million DKK | 2.99% |
| 2016 Q2 | 406 Million DKK | 11.23% |
| 2016 Q3 | 481 Million DKK | 18.47% |
| 2016 Q4 | 483 Million DKK | 0.42% |
| 2016 Q1 | 365 Million DKK | -22.17% |
| 2015 Q3 | 248 Million DKK | 25.89% |
| 2015 FY | 469 Million DKK | 1240.0% |
| 2015 Q4 | 469 Million DKK | 89.11% |
| 2015 Q2 | 197 Million DKK | 137.35% |
| 2015 Q1 | 83 Million DKK | 137.14% |
| 2014 Q4 | 35 Million DKK | -59.3% |
| 2014 FY | 35 Million DKK | 133.33% |
| 2014 Q1 | 36 Million DKK | 140.0% |
| 2014 Q2 | 27 Million DKK | -25.0% |
| 2014 Q3 | 86 Million DKK | 218.52% |
| 2013 Q3 | 70 Million DKK | 89.19% |
| 2013 Q4 | 15 Million DKK | -78.57% |
| 2013 FY | 15 Million DKK | 110.34% |
| 2013 Q1 | -115 Million DKK | 20.69% |
| 2013 Q2 | 37 Million DKK | 132.17% |
| 2012 Q2 | -159 Million DKK | 58.05% |
| 2012 Q1 | -379 Million DKK | 9.76% |
| 2012 FY | -145 Million DKK | 65.48% |
| 2012 Q4 | -145 Million DKK | 11.59% |
| 2012 Q3 | -164 Million DKK | -3.14% |
| 2011 FY | -420 Million DKK | -107.92% |
| 2011 Q1 | -471 Million DKK | -133.17% |
| 2011 Q2 | -394 Million DKK | 16.35% |
| 2011 Q3 | -366 Million DKK | 7.11% |
| 2011 Q4 | -420 Million DKK | -14.75% |
| 2010 Q1 | -373 Million DKK | 2.86% |
| 2010 FY | -202 Million DKK | 47.4% |
| 2010 Q4 | -202 Million DKK | -129.55% |
| 2010 Q3 | -88 Million DKK | 67.16% |
| 2010 Q2 | -268 Million DKK | 28.15% |
| 2009 Q4 | -384 Million DKK | 0.0% |
| 2009 FY | -384 Million DKK | 10.49% |
| 2008 FY | -429 Million DKK | 55.36% |
| 2007 FY | -961 Million DKK | 2.44% |
| 2006 FY | -985 Million DKK | 81.94% |
| 2005 FY | -5.45 Billion DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bavarian Nordic A/S | -1.33 Billion DKK | 121.848% |
| Genmab A/S | -14.09 Billion DKK | 102.064% |
| Gubra A/S | 18.03 Million DKK | -1513.261% |
| Novo Nordisk A/S | 12.61 Billion DKK | 97.693% |
| Orphazyme A/S | -11.26 Million DKK | 2682.305% |
| Pharma Equity Group A/S | 25.99 Million DKK | -1019.661% |
| Zealand Pharma A/S | -249.03 Million DKK | 216.851% |